Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx<sup>®</sup>): a placebo-controlled randomised phase II study (PLIANT)
-
- Bengt Glimelius
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden;
-
- Nebojsa Manojlovic
- Clinic for Gastroenterology and Hepatology of Military Medical Academy of Serbia, Belgrade, Serbia;
-
- Per Pfeiffer
- Department of Oncology, Odense University Hospital, Odense, Denmark;
-
- Baadur Mosidze
- LTD High Technology Medical Center, University Clinic, Tbilisi, Georgia;
-
- Galina Kurteva
- Clinic of Chemotherapy, SHATO EAD, Sofia, Bulgaria;
-
- Mia Karlberg
- Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden;
-
- Devalingam Mahalingam
- Cancer Therapy and Research Center, The University of Texas Health Science Center San Antonio, San Antonio, TX, USA;
-
- Peter Buhl Jensen
- Buhl Oncology, Copenhagen, Denmark;
-
- Jan Kowalski
- JK Biostatistics, Stockholm, Sweden
-
- Marie Bengtson
- PledPharma AB, Stockholm, Sweden;
-
- Malin Nittve
- PledPharma AB, Stockholm, Sweden;
-
- Jacques Näsström
- PledPharma AB, Stockholm, Sweden;
Journal
-
- Acta Oncologica
-
Acta Oncologica 57 (3), 393-402, 2017-11-15
MJS Publishing, Medical Journals Sweden AB
- Tweet
Details 詳細情報について
-
- CRID
- 1361699995634017024
-
- ISSN
- 1651226X
- 0284186X
-
- Data Source
-
- Crossref